NNNiccolò Napoli

Niccolò Napoli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Niccolò Napoli has a total of 590 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Postpancreatectomy Mortality (PPM) Following Minimally Invasive Pancreatic Surgery Is Mainly Driven by Pancreatectomy-Specific Complications

    by Riccardo Turrini, Tommaso Giuliani, Giovanni Marchegiani, Niccolò Napoli, Giovanni Butturini, Alessandro Esposito, Giovanni Ferrari, Massimo Falconi, Luca Morelli, Giovanni Capretti, et al.

    Background: Postpancreatectomy mortality (PPM) remains relatively unexplored after minimally invasive pancreatic surgery (MIPS). The International Study Group for Pancreatic Surgery (ISGPS) recently proposed a consensus definition and classification of PPM based on root-cause analysis. We aimed to assess the applicability of this classification and characterize mechanisms of PPM following MIPS. Methods: This study retrospectively analyzed consecutive patients undergoing MIPS enrolled in the Italian IGoMIPS registry (October 2019–July 2025). All PPM events were reviewed and attributed specific PPM types using structured root-cause analysis according to ISGPS criteria. Multivariable logistic regression identified predictors of PPM, and PPM type distributions were compared across procedures. Results: Out of 3590 patients, the PPM rate was 2.7%. Specifically, PPM occurred in 5.9% following minimally invasive pancreatoduodenectomy (MIPD), 0.8% following left pancreatectomy (MILP), and 4.8% following total pancreatectomy (MITP), while no PPM events occurred after parenchyma-sparing resections. Increased age and American Society of Anesthesiology Physical Status (ASA-PS) ≥3 independently predicted PPM. Root-cause analysis showed that most PPM followed cascades of multiple pancreatectomy-specific complications, predominantly postoperative pancreatic fistula (POPF) and postpancreatectomy hemorrhage (PPH). PPM 2 accounted for approximately two-thirds of deaths, particularly after MIPD and MITP, whereas PPM 1 and PPM 3 accounted for 13.3% and 15.3%, respectively. Conclusions: Mortality after MIPS predominantly occurs after a cascade of pancreatectomy-specific complications rather than technical failure or isolated medical events. Centers performing MIPS should invest in strategies to mitigate POPF and PPH and minimize failure to rescue once they occur.

  • Open Access

    International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot

    by Chiara D'ALterio, Quirino Lai, Maria Lanzone, Roberto Valente, Matteo Fabbrici da Correggio, Immacolata Iannone, Alessandro Coppola, Salah Berkane, Tomas Koltai, Lucas McCormack, et al.

  • Robotics vs. laparoscopy in spleen-preserving distal pancreatectomy in the IGOMIPS registry: when glitter does not equal superiority

    by Niccolò Napoli, Michael Ginesini, Allegra Ripolli, Alessandro Esposito, Massimo Falconi, Giovanni Ferrari, Carlo Molino, Luca Morelli, Roberto Salvia, Alessandro Zerbi, et al.

    Spleen-preserving distal pancreatectomy (SPDP) reduces the risks associated with splenectomy and can be performed laparoscopically (Lap-SPDP) or robotically (Rob-SPDP). Whether robotic assistance improves spleen preservation compared with laparoscopy remains unclear. A retrospective cohort study was conducted using the prospective Italian Registry of Minimally Invasive Pancreatic Surgery (IGOMIPS). All consecutive patients scheduled for SPDP between September 2019 and July 2024 were analyzed according to an intention-to-treat protocol. Primary endpoint was intraoperative deviation from planned SPDP; secondary endpoints included intra- and postoperative outcomes. Propensity score matching was performed to adjust for baseline variables, with a second propensity score matching including center volume and surgeon experience. Of 3045 procedures, 270 were planned SPDP (Rob-SPDP n = 138, Lap-SPDP n = 132). Overall intraoperative deviation occurred in 22.6% of cases, most commonly conversion to distal pancreatectomy with splenectomy. Spleen-vessel preservation rates were similar for Rob-SPDP (87.9) and Lap-SPDP (90.6%; p = 0.5561). Robotic procedures had longer operative time but lower stapler use. No significant differences were observed in severe complications, mortality, length of stay, or other postoperative outcomes in unmatched or matched cohorts. Robotic use increased significantly over time and was predominant in centers with robotic platforms and higher volumes. In a prospective national registry, Lap-SPDP and Rob-SPDP achieved comparable spleen preservation rates and perioperative outcomes. Robotic assistance did not confer measurable clinical advantages, though its adoption is increasing, particularly in high-volume, well-equipped centers.


  • Robotic Pancreaticoduodenectomy with Vascular Resection and Reconstruction

    by Niccolò Napoli, Emanuele F. Kauffmann, Michael Ginesini, Ugo Boggi

  • Navigating the learning curve of robotic pancreatoduodenectomy: Competency, proficiency, and mastery in a first-generation robotic surgeon with established open pancreatic expertise

    by Niccolò Napoli, Michael Ginesini, Emanuele Federico Kauffmann, Linda Barbarello, Fabio Caniglia, Francesca Costa, Carlo Lombardo, Vittorio Grazio Perrone, Virginia Viti, Gabriella Amorese, et al.


  • Open Access

    External Validation of the International Study Group for Pancreatic Surgery Complexity Grading System for Minimally Invasive Pancreatoduodenectomy

    by Niccolò MD Napoli, Greta Donisi, Emanuele Federico Kauffmann, Michael Ginesini, Mohammad Abu Hilal, Gian Luca Baiocchi, Umberto Bracale, Alberto Brolese, Giovanni Butturini, Roberto Coppola, et al.

    Objective: To validate the International Study Group for Pancreatic Surgery (ISGPS) complexity grading system for minimally invasive pancreaticoduodenectomy (MIPD). Background: Although concerns about patient safety persist, MIPD is gaining popularity. The ISGPS recently introduced a difficulty grading system to improve patient selection by aligning procedural complexity with surgeon and center expertise. Methods: Data from MIPD cases reported in the IGOMIPS registry (October 2019–February 2024) were analyzed, with severe postoperative complications as the primary outcome. Logistic regression was used to identify risk factors for complications. Results: Of the 771 MIPD cases, 426 (55.3%) were analyzed. A pancreatic duct size ≤3 mm was the only significant risk factor for severe complications (odds ratio = 2.22, P = 0.0001). Most cases (n = 255; 59.9%) were classified as grade C complexity, whereas 22 (5.1%) were classified as grade A. Severe postoperative complications increased with complexity (grade A, 31.8%; grade B, 36.3%; grade C, 48.6%; P = 0.0091). For grade A complexity, the outcomes were consistent across surgeons and centers. Grade B outcomes were similar between grade B and C centers but superior to grade A centers. In grade C cases, outcomes were comparable between grade A and B centers, with improvements at grade C centers. Grade A ISGPS experience correlated strongly with mismatches between planned and performed procedures (grade A, 15.0%; grade B, 3.0%; grade C, 3.1%; P < 0.0001), including total pancreatectomy (grade A, 11.5%; grade B, 1.2%; grade C, 3.1%; P = 0.0005). Conclusions: The ISGPS complexity grading system effectively predicted MIPD outcomes, supporting better patient selection and alignment of complexity with surgical expertise.


  • Open Access

    Preoperative carbohydrate antigen 19.9 level predicts lymph node metastasis in resectable adenocarcinoma of the head of the pancreas: a further plea for biological resectability criteria

    by Alessandro Coppola, Vincenzo La Vaccara, Tommaso Farolfi, Horacio J. Asbun, Ugo Boggi, Kevin Conlon, Bjørn Edwin, Cristina Ferrone, Eduard Jonas, Norihiro Kokudo, et al.

    Introduction: Lymph-nodal involvement (N+) represents an adverse prognostic factor after pancreatoduodenectomy (PD) for pancreatic adenocarcinoma (PDAC). Preoperative diagnostic and staging modalities lack sensitivity for identifying N+. This study aimed to investigate preoperative carbohydrate antigen 19.9 (CA 19.9) in predicting the N+ stage in resectable-PDAC (R-PDAC). Methods: Patients included in a multi-institutional retrospective database of PDs performed for R-PDAC from January 2000 to June 2021 were analysed. A preoperative laboratory value of CA 19.9 greater than 37 U/l was used in univariate and multivariate logistic regression analysis to determine a possible association with N+. Additionally, different cut-offs of CA 19.9 related to the preoperative clinical T (cT) stage was assessed to evaluate the risk of N+. Results: A total of 2034 PDs from thirteen centres were included in the study. CA 19.9 greater than 37 U/l was significantly associated with higher N+ at univariate and multivariate analysis (P<0.001). CA 19.9 levels greater than 37 U/l were associated with N+ in 75.9%, 81.3%, and 85.7% of patients, respectively, in cT1, cT2, and cT3 tumours and with higher cut-off values for all cT stages. Conclusion: Lymph-nodal involvement is strongly related to preoperative CA 19.9 levels. Specially in patients staged as cT3 the CA 19.9 could represent a valid and easy tool to suspect nodal involvement. Due to these findings, R-PDAC patients with elevated CA 19.9 values should be considered in a more biologically advanced stage.


  • Open Access

    Ca 125 is an independent prognostic marker in resected pancreatic cancer of the head of the pancreas

    by Niccolò Napoli, Emanuele F. Kauffmann, Michael Ginesini, Lucrezia Lami, Carlo Lombardo, Fabio Vistoli, Daniela Campani, Ugo Boggi

    The prognostic value of carbohydrate antigen 125 (Ca 125) is emerging also in pancreatic cancer (PDAC). In this study, we aim to define the prognostic value of Ca 125 in resected PDAC of the head of the pancreas. This is a single-center, retrospective study. Data from patients with a pre-operative assay of Ca 125 who underwent a pancreatic resection for PDAC between 2010 and 2018 were analyzed. As per National Comprehensive Cancer Guidelines, tumors were classified in resectable (R-PDAC), borderline resectable (BR-PDAC), and locally advanced (LA-PDAC). The Kaplan–Meier method was used to evaluate the overall survival. Cox proportional hazard regression was used to evaluate the role of pre-operative Ca 125 in predicting survival (while adjusting for confounders). The maximally selected log-rank statistic was used to identify a Ca 125 cut-off defining two groups with different survival probability. Inclusion criteria were met by 207 patients (R-PDAC: 80, BR-PDAC: 91, and LA-PDAC: 36). Ca 125 predicted overall survival before and after adjusting for confounding factors in all categories of anatomic resectability (R-PDAC: HR = 4.3; p = 0.0249) (BR-PDAC: HR = 7.82; p = 0.0024) (LA-PDAC: HR = 11.4; p = 0.0043). In BR-PDAC and LA-PDAC (n = 127), the division in two groups (high vs. low Ca 125) correlated with T stage (p = 0.0317), N stage (p = 0.0083), mean LN ratio (p = 0.0292), and tumor grading (p = 0.0143). This study confirmed the prognostic value of Ca125 in resected pancreatic cancer and, therefore, the importance of biologic over anatomic resectability. Ca 125 should be routinely assayed in surgical candidates with PDAC.


  • Open Access

    Practical implications of tumor proximity to landmark vessels in minimally invasive radical antegrade modular pancreatosplenectomy

    by Emanuele Federico Kauffmann, Niccolò Napoli, Armando Di Dato, Alice Salamone, Michael Ginesini, Cesare Gianfaldoni, Virginia Viti, Gabriella Amorese, Carla Cappelli, Fabio Vistoli, et al.

    Careful preoperative planning is key in minimally invasive radical antegrade modular pancreatosplenectomy (MI-RAMPS). This retrospective study aims to show the practical implications of computed tomography distance between the right margin of the tumor and either the left margin of the spleno-mesenteric confluence (d-SMC) or the gastroduodenal artery (d-GDA). Between January 2011 and June 2022, 48 minimally invasive RAMPS were performed for either pancreatic cancer or malignant intraductal mucinous papillary neoplasms. Two procedures were converted to open surgery (4.3%). Mean tumor size was 31.1 ± 14.7 mm. Mean d-SMC was 21.5 ± 18.5 mm. Mean d-GDA was 41.2 ± 23.2 mm. A vein resection was performed in 10 patients (20.8%) and the pancreatic neck could not be divided by an endoscopic stapler in 19 operations (43.1%). In patients requiring a vein resection, mean d-SMC was 10 mm (1.5–15.5) compared to 18 mm (10–37) in those without vein resection (p = 0.01). The cut-off of d-SMC to perform a vein resection was 17 mm (AUC 0.75). Mean d-GDA was 26 mm (19–39) mm when an endoscopic stapler could not be used to divide the pancreas, and 46 mm (30–65) when the neck of the pancreas was stapled (p = 0.01). The cut-off of d-GDA to safely pass an endoscopic stapler behind the neck of the pancreas was 43 mm (AUC 0.75). Computed tomography d-SMC and d-GDA are key measurements when planning for MI-RAMPS.


  • Management of Complications Occurring After Pancreas Transplantation

    by Fabio Vistoli, Emanuele Federico Kauffmann, Niccolò Napoli, Gabriella Amorese, Ugo Boggi